Marker Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.69next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
| FY 2026 Annual Earnings Release | 18 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Restricted Cash Quarterly15.6MTarget: Sufficient capital to fund operations through clinical milestones
Quarterly Net Loss Quarterly-3.2MTarget: Narrowing loss through disciplined R&D spending and grant offsets
Grant Income (Other Income) Quarterly751.7KTarget: Maximize non-dilutive funding from NIH, CPRIT, and FDA
Watch Items
- Cash Runway and Going Concern RiskTrigger: Cash reserves falling below $10 million without additional non-dilutive or equity fundingAction: Pursue secondary equity offerings, ATM facility utilization, or new strategic partnerships to extend runway beyond Q1 2027.
- MT-601 Phase 1 APOLLO Trial Progress in LymphomaTrigger: Completion of dose expansion phase enrollment in Diffuse Large B Cell Lymphoma (DLBCL)Action: Review clinical efficacy (ORR/CRR) and safety data to prepare for a potential pivotal trial design.
- MT-601 Pancreatic Cancer Program InitiationTrigger: First patient treated in the Phase 1 trial combining MT-601 with frontline chemotherapyAction: Monitor safety profiles and early disease control rates (DCR) to validate solid tumor application.
- Nasdaq Listing ComplianceTrigger: Stockholders' equity falling below the Nasdaq Capital Market minimum requirementAction: Execute capital-raising strategies or obtain shareholder approval for share structure adjustments to maintain listing status.
Research as of 20 Jun 2026